2seventy bio Completes Strategic Asset Transfer to Regeneron, Pivots Entirely to Abecma Commercialization

2seventy bio has successfully finalized its transformative divestiture agreement with Regeneron Pharmaceuticals, marking a decisive shift in the company’s strategic direction. Through this transaction, Regeneron has acquired the entire portfolio of oncology and autoimmune research initiatives, along with approximately 160 team members who will establish Regeneron’s newly formed cell medicines division.

Streamlined Operations and Extended Financial Runway

Following this restructuring, 2seventy bio now operates as a leaner organization with roughly 65 permanent full-time employees focused on quality assurance and operational support functions. The financial benefits derived from workforce optimization and asset monetization have substantially improved the company’s cash position, with projections now extending well beyond 2027. This fiscal stability provides the necessary runway for the company to execute its concentrated business strategy without near-term funding pressures.

Exclusive Focus on Abecma Development

The biotech firm has redirected its entire operational scope toward advancing Abecma (idecabtagene vicleucel), a BCMA-targeted CAR T cell immunotherapy designed to treat multiple myeloma patients. This singular focus represents a fundamental departure from the company’s previous multi-program approach. Chip Baird, serving as CEO, emphasized the significance of this transition: “The completion of our Regeneron partnership allows 2seventy bio to concentrate fully on maximizing Abecma’s potential. We’re enthusiastic about the talented individuals joining Regeneron Cell Medicines and their continued contributions to developing breakthrough cancer treatments. Simultaneously, we’re energized by the prospect of extending Abecma access to patients across earlier disease stages.”

Strategic Partnership and Manufacturing Support

2seventy bio maintains its collaborative relationship with Bristol Myers Squibb (BMS) regarding Abecma’s advancement and market distribution. The company will retain responsibility for quality control oversight of lentiviral vector production, a critical component in the Abecma manufacturing process. This division of responsibilities allows 2seventy bio to concentrate resources on its core mission while ensuring continuity in the supply chain.

Market Positioning and Future Trajectory

This realignment positions 2seventy bio to function as a specialized entity dedicated to unlocking maximum commercial value from its lead therapeutic asset. The company’s operational efficiency improvements and extended capital runway create a sustainable foundation for pursuing its ambitions of bringing Abecma to an expanded patient population across multiple treatment phases. The strategic clarity resulting from this transaction enables management to allocate resources with precision toward commercialization acceleration and manufacturing expansion initiatives.